Table 1.
Characteristics of clinical trials included in the single-arm meta-analysis.
| Study | Year | Register number | Country | Patients | Histology | Age (years) | Male (%) | Phase | Design |
|---|---|---|---|---|---|---|---|---|---|
| Herbst et al. (18) | 2019 | NCT02443324 | 5-countries* | 27 | NSCLC | 65.0 | 78.0% | Ia/Ib | Single-arm |
| Galffy et al. (19) | 2020 | NCT03472560 | Hungary | 41 | NSCLC | NR | NR | II | Single-arm |
| Bang et al. (20) | 2020 | NCT02572687 | 8-countries^ | 28 | NSCLC | 64.5 | 68.0% | Ia/Ib | Single-arm |
| Zhou et al. (21) | 2021 | NCT04670107 | China | 45 | NSCLC | 62.0 | 72.5% | Ib | Single-arm |
| Puri et al. (22) | 2021 | NCT03377023 | USA | 18 | NSCLC | NR | 66.7% | Ib/II | Single-arm |
| Pan et al. (23) | 2021 | ChiCTR2000034597 | China | 10 | NSCLC | NR | 33.3% | II | Single-arm |
| Zhou et al. (24) | 2021 | NCT04203485 | China | 105 | N-Sq NSCLC | 58.0 | 75.2% | Ib/II | Single-arm |
| Han et al. (25) | 2021 | NCT03910127 | China | 68 | NSCLC | NR | NR | II | RCT |
| Leal et al. (26) | 2022 | NCT02954991 | USA | 68 | N-Sq NSCLC | 66.0 | 43.0% | II | Single-arm |
| Fang et al. (27) | 2022 | NCT04426825 | China | 19 | EGFR+NSCLC | 63.0 | 42.0% | II | Single-arm |
| Reckmap et al. (28) | 2022 | NCT03971474 | USA | 69 | NSCLC | 66.4 | 59.0% | II | RCT |
| Lv et al. (29) | 2022 | ChiCTR1900023664 | China | 34 | NSCLC | 60.0 | 67.6% | II | Single-arm |
| Lu et al. (30) | 2022 | NCT03802240 | China | 158 | EGFR+ NSCLC | 58.5 | 41.1% | III | RCT |
| Lee et al. (31) | 2022 | NCT03616691 | Korea | 24 | NSCLC | 63.0 | 54.2% | II | Single-arm |
| Herzog et al. (32) | 2022 | NCT03689855 | USA | 21 | NSCLC | 67.0 | 19.0% | II | Single-arm |
| Gao et al. (33) | 2022 | NCT03083041 | China | 25 | Sq NSCLC | 63.0 | 92.0% | II | Single-arm |
| Neal et al. (34) | 2022 | NCT03170960 | 9-countries# | 81 | N-Sq NSCLC | 67.0 | 57.0% | Ib | Single-arm |
| Gao et al. (35) | 2022 | NCT03666143 | China | 47 | NSCLC | 60.0 | NR | Ib | Single-arm |
| Gao et al. (36) | 2022 | NCT03083041 | China | 43 | EGFR/ALK+ NSCLC |
55.0 | 58.1% | II | Single-arm |
5-countries*: USA, France, Germany, Spain and the UK; 8-countries^: France, Germany, Israel, Italy, Republic of Korea, Spain, Taiwan, and the USA; 9-countries#: Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom and the USA.